Attend “An overview of the JAX Human PDX Tumor Repository” presented by Rick Huntress, Director of
Commercial Business Development at The Jackson Laboratory.
Learn more about:
The JAX Human PDX Tumor Repository
Best Practices for preclinical studies in vivo studies utilizing PDX tumors
Insourcing and outsourcing options for PDX models and studies utilizing PDX models will also be presented
July 17th10:10 a.m.
Panel Discussion: “The Changing Expectations of Model Requirements”
Join industry leaders and Rick Huntress from The Jackson Laboratory.
Check out The Jackson Laboratory poster: Utility of human FcRn transgenic mice for preclinical screening of immunotherapeutics.
JAX’s In Vivo Pharmacology group evaluates the pharmacokinetics, bioavailability and efficacy of therapeutic monoclonal antibodies and albumin-conjugates in vivo, using unique JAX-generated FcRn-humanized models. These models use transgenic mice that uniquely express the human Fc receptor neonatal (hFcRn). To demonstrate the utility of the hFcRn Tg mouse model platform, three immunotherapeutics (pembrolizumab, ipilimumab, and belatacept) were administered IV to Tg32, Tg276, FcRn null, and B6 wild type mice. The mice were blood sampled (25 µL) at 1, 3, 5, 7, 9, 12, 16, 19, 22, 26, and 30 days. Immunotherapeutic plasma concentrations, assessed by human IgG ELISA, were pharmacokinetically analyzed. Tg32 mice yielded half-life values for these immunotherapeutics with ranges that mimicked patient data. Though reduced in scale, Tg276 mice also produced half-life data that correlated with the established human half-life data for pembrolizumab, ipilimumab, and belatacept. These results confirm that the human FcRn Tg model platform can be broadly applied to preclinical pharmacokinetic screening of mAb and Fc-fusion based immunotherapeutics.